RESHAPE LIFESCIENCES INC (RSLS)

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023;...

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

Patent Significantly Strengthens Intellectual Property Portfolio

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

Patent Significantly Strengthens Intellectual Property Portfolio...

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for...

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif.,...

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons...

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic...

Why Is Shattuck Labs (STTK) Stock Up 93% Today?

Shattuck Labs stock is rising on Wednesday after the company provided positive initial results from a Phase 1 clinical trial.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With ‘Overweight’ Rating

Roblox stock is rising higher on Wednesday after Wells Fargo initiated coverage of RBLX shares wit a bullish rating and price target.

PLTR Stock: Palantir Renews UniCredit Partnership

Palantir Technologies stock is slipping on Wednesday even with positive news for PLTR investors in the form of a renewed contract.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

ReShape Lifesciences stock is rising with heavy trading of RSLS shares alongside an update from the FDA concerning its weight loss products.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!

ReShape Lifesciences stock spikes as FDA clears new Lap-Band

ReShape Lifesciences (RSLS) soars as FDA approves Lap-Band 2.0 FLEX, an innovative treatment for obesity. Read more here.

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) --...

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health...

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023